GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
L

Larkberget LARK.ST · SEK

Health Care · Nasdaq Stockholm · 🇸🇪 Sweden

Compare

2.30

+1.77%

Close of 9 Nov 2026, in SEK

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Larkberget

Its shares trade on Nasdaq Stockholm under the ticker LARK.ST. It has been listed since 25 May 2015. In the fiscal year to 31 December 2024, it reported revenue of SEK 326,000 and a net loss of SEK 44.9m. At that date it held total assets of SEK 75.9m and shareholders' equity of SEK 71.6m.

CombiGene AB engages in the development of new treatment for neurological diseases. The company is headquartered in Lidingoe, Stockholm. The company went IPO on 2015-05-25. The firm specializes in development of treatments for neurological disorders. The firm's platform comprises the use of gene therapy vectors delivering a combination of transgenes encoding two or more of neuropeptide Y (NPY) receptors, galanin, galanin receptors, somatostatin, and somatostatin receptors, for the treatment of neurological and psychiatric diseases in humans and animals. The firm focuses on the development of an epilepsy treatment by means of an adeno-associated virus (AAV) vector carrying the transgenes for the neurotransmitter NPY and one of its receptors, the G protein-coupled receptor Y2.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
25 May 2015

Leadership

Pay as last reported

  • Mr. Robert KlatzkowChairman of the Board, since 2025
  • Mr. Luca Di StefanoInterim Chief Executive Officer, Executive Director, since 2025
  • Ms. Louise AspenbergChief Financial Officer
  • Ms. Annika EricssonChief Scientific Officer
  • Mr. Alexander GradinDirector
  • Mr. Marcus IsakssonDirector

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Company is focused on developing treatments for neurological diseases.
  • Specializes in gene therapy vectors for neurological and psychiatric diseases.
  • Has a platform using transgenes for NPY receptors and related therapies.

Weaknesses

  • No specific financial data provided for the company.
  • No details on current market position or competitive advantages.
  • Limited information on product development stages or clinical trials.

Opportunities

  • Potential growth in neurological disease treatment market.
  • Expanding applications of gene therapy in psychiatric conditions.
  • Opportunities for partnerships in biotechnology sector.

Threats

  • Unverified claims in source description may affect credibility.
  • Lack of detailed financial or operational data raises uncertainty.
  • Competition in biotechnology sector could impact market share.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.